Ticlopid250 mg

Ticlopid is an antiplatelet medicine belonging to the thienopyridine class. Because of its serious hematologic side-effect profile, it is generally reserved for patients who cannot tolerate or have failed other antiplatelet therapies (such as aspirin or clopidogrel).

• Established/FDA-approved use: Reduction of the risk of thrombotic stroke (fatal or non-fatal) in patients who have experienced stroke precursors (e.g., transient ischemic attacks) or who have had a completed thrombotic stroke.
• Established/FDA-approved use (combination therapy): Prevention of subacute stent thrombosis, used in combination with aspirin, following successful coronary artery stent implantation.

Ticlopid is typically considered a second-line antiplatelet agent rather than a first-choice therapy, due to the availability of alternatives with a more favorable safety profile.

Each film-coated tablet of Ticlopidine Hydrochloride typically contains 250 mg of ticlopidine hydrochloride as the active ingredient, together with standard pharmaceutical excipients used in tablet formulation.

Ticlopid is an orally administered antiplatelet agent of the thienopyridine chemical class. It works by irreversibly blocking adenosine diphosphate (ADP)-mediated platelet activation and aggregation, thereby reducing the likelihood of thrombus (blood clot) formation. It shares a similar mechanism of action with other thienopyridines such as clopidogrel, but carries a distinct and more significant risk of serious blood-cell disorders, which limits its use to selected clinical situations.

Ticlopid belongs to the therapeutic class of antiplatelet agents, specifically the thienopyridine subclass of ADP-receptor (P2Y12) inhibitors.

Ticlopidine Hydrochloride is a prodrug that requires hepatic metabolism to form an active metabolite. This active metabolite irreversibly binds to the P2Y12 subtype of the ADP receptor on the platelet surface, blocking ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. This prevents fibrinogen from binding to platelets, inhibiting platelet-to-platelet aggregation for the remaining lifespan of the platelet (approximately 7-10 days). The onset of measurable antiplatelet effect is gradual, typically becoming apparent within 2 days and reaching maximum effect after 3-5 days of repeated dosing; platelet function gradually returns to normal over 1-2 weeks after discontinuation.

Ticlopid tablets should be taken by mouth, with food or immediately after meals, to minimize gastrointestinal side effects. Tablets should be swallowed whole and should not be crushed or chewed unless directed otherwise by a physician. Do not stop or change the dose without consulting the prescribing physician.

• Aspirin and other antiplatelet agents: Combined use increases the risk of bleeding; used together only under close medical supervision (e.g., for stent thrombosis prevention).
• Anticoagulants (e.g., warfarin): Increased risk of serious bleeding; concurrent use requires careful monitoring.
• NSAIDs: Additive increase in gastrointestinal bleeding risk.
• Theophylline: Ticlopid inhibits its hepatic metabolism (CYP1A2), which can raise theophylline blood levels and increase the risk of toxicity; theophylline dose adjustment and monitoring may be needed.
• Phenytoin: Ticlopid may increase phenytoin plasma levels through metabolic inhibition (CYP2C19), raising the risk of phenytoin toxicity.
• Cimetidine: May increase plasma concentrations of Ticlopid.
• Antacids: May reduce the absorption and plasma levels of Ticlopid when taken together.
• Cyclosporine: Ticlopid has been reported to decrease cyclosporine plasma levels; monitoring is advised.

Common side effects of Ticlopid include:

• Diarrhea and gastrointestinal upset (common)
• Nausea, dyspepsia, abdominal pain
• Skin rash
• Elevated blood cholesterol and triglyceride levels
• Bruising or minor bleeding (e.g., nosebleeds, gum bleeding)

Serious but less common effects requiring immediate medical attention include severe neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP), aplastic anemia, serious bleeding, and liver enzyme abnormalities (see Precautions and Warnings).

The safety of Ticlopid in human pregnancy has not been well established, and data are limited. Ticlopid should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. It is not known whether Ticlopid passes into breast milk; because many drugs are excreted in human milk and given the potential for serious adverse reactions in a nursing infant, a decision should be made in consultation with a physician whether to discontinue nursing or discontinue the drug.

Ticlopid carries important safety warnings and requires close medical supervision:

• Life-threatening hematologic reactions (boxed warning): Neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP), and aplastic anemia have been reported. Complete blood counts with differential should be monitored regularly, particularly every two weeks during the first three months of therapy. Discontinue Ticlopid immediately and seek medical attention if fever, sore throat, unusual bruising or bleeding, or other signs of infection occur.
• Bleeding risk: Increased risk of bleeding, particularly when combined with other antiplatelet agents, anticoagulants, or NSAIDs. Ticlopid should be discontinued as directed by the physician (commonly about 10-14 days) before elective surgery.
• Hepatic effects: Liver enzyme abnormalities and, rarely, hepatitis or cholestatic jaundice have been reported; liver function should be monitored, especially during the first months of treatment.
• Gastrointestinal effects: Diarrhea and other GI upset are common; report severe or persistent symptoms to a physician.

Ticlopid is not an antibiotic; nonetheless, given its serious safety profile, take it exactly as prescribed by your physician and do not stop, extend, skip doses, or share this medicine with others without medical advice.

There is limited clinical experience with overdose of Ticlopid. Expected manifestations of overdose may include an increased bleeding tendency and gastrointestinal symptoms. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment should be supportive and managed by medical professionals; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment: Ticlopid is contraindicated in patients with severe hepatic impairment; use with caution and close liver function monitoring in patients with mild to moderate hepatic dysfunction.

Renal impairment: No formal, well-established dose adjustment has been defined; use with caution and appropriate monitoring.

Elderly: No specific dose adjustment is generally required, but elderly patients should be monitored closely for bleeding and hematologic side effects.

Pediatric patients: Safety and efficacy of Ticlopid have not been established in children (see Pediatric Uses).

The duration of treatment with Ticlopid depends on the indication and is determined by the treating physician. For reduction of stroke risk it may be used long-term with regular monitoring, while for prevention of subacute stent thrombosis it is typically used in combination with aspirin for a limited period (commonly up to about 30 days) following stent placement, as directed by the physician.

Antiplatelet agents; Thienopyridines; ADP (P2Y12) receptor inhibitors.

Ticlopidine Hydrochloride is metabolized in the liver to an active metabolite that irreversibly inhibits the ADP-mediated pathway of platelet activation by blocking the P2Y12 receptor, preventing platelet aggregation and reducing thrombus formation for the remaining lifespan of the affected platelets.

B

The safety and efficacy of Ticlopid have not been established in pediatric patients. Ticlopid is therefore not recommended for use in children, and pediatric dosing has not been established.